May 2, 2018 / 11:08 AM / 4 months ago

BRIEF-Janssen To Acquire Benevir Biopharm To Advance Immunotherapy Regimens

May 2 (Reuters) - Johnson & Johnson:

* JANSSEN TO ACQUIRE BENEVIR BIOPHARM TO ADVANCE IMMUNOTHERAPY REGIMENS

* JANSSEN BIOTECH- ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH IT WILL ACQUIRE BENEVIR BIOPHARM

* JANSSEN BIOTECH - BENEVIR WILL MAINTAIN A RESEARCH PRESENCE IN ROCKVILLE, MARYLAND AND BECOME PART OF JANSSEN ONCOLOGY THERAPEUTIC AREA

* JANSSEN BIOTECH - JOHNSON & JOHNSON INNOVATION LLC FACILITATED TRANSACTION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below